ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib mesylate (IM) and other BCR-ABL tyrosine kinase inhibitors (BCR-ABLi) are the mainstay of chronic myelogenous leukemia (CML) treatment.